The post New Data Reveals Which Wall Street Firms Sold Bitcoin ETFs appeared on BitcoinEthereumNews.com. Large US investors reduced their Bitcoin ETF holdings inThe post New Data Reveals Which Wall Street Firms Sold Bitcoin ETFs appeared on BitcoinEthereumNews.com. Large US investors reduced their Bitcoin ETF holdings in

New Data Reveals Which Wall Street Firms Sold Bitcoin ETFs

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Large US investors reduced their Bitcoin ETF holdings in late 2025, and new breakdowns show the selling came mainly from a few specific groups rather than the entire market.

Bloomberg Intelligence data shared by analysts shows that 13F filers — large institutions that report quarterly holdings to the US SEC — were net sellers of Bitcoin ETFs in Q4 2025, cutting exposure by nearly $1.6 billion.

The biggest reductions came from investment advisors and hedge funds, the two largest holder categories.

13F Filers Sold Their Bitcoin Shares

A 13F filer is a large US money manager (usually with over $100 million in qualifying assets) that must report its holdings every quarter. These filings show a snapshot of positions at quarter-end.

These firm’s reported Bitcoin ETF holdings were lower in Q4 than in Q3. In other words, they reduced ETF shares, not necessarily that they sold physical Bitcoin directly on exchanges.

US Bitcoin ETF Inflow and Outflow in 2026. Source: SoSoValue

That helps explain why Bitcoin has remained under pressure even during short-term rebounds. ETF flow data shows repeated daily outflows in recent weeks, including several large red days in February.

Who Sold the Most

The category-level data shows the largest net reductions came from:

  • Investment Advisors: about -21,831 BTC
  • Hedge Fund Managers: about -7,694 BTC

Other categories, such as brokerages and banks also reduced exposure. 

However, some groups increased holdings, including holding companies and government-related entities.

Bitcoin Price Chart Over the Past Month: Source: CoinGecko

This does not mean “all institutions turned bearish.” Many firms use Bitcoin ETFs for hedging, arbitrage, or short-term trading, not just long-term bets.

However, the broader signal is clear. Big-money positioning weakened, and that matches the recent ETF outflow trend. 

Until daily ETF flows stabilize and turn positive for more than a few sessions, Bitcoin may remain in a fragile, relief-rally phase rather than a full recovery.

Source: https://beincrypto.com/wall-street-sold-bitcoin-etfs-13f-filings-data/

Market Opportunity
Bitcoin Logo
Bitcoin Price(BTC)
$68,029.99
$68,029.99$68,029.99
-0.69%
USD
Bitcoin (BTC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09